Sec. 751. Testosterone levels among members of special forces of the Army: study; report
269 words·~1 min read·
/bill/118/hr/2670/eh/section-751·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Under Secretary of Defense for Personnel and Readiness shall conduct a five-year study, beginning in fiscal year 2024, with respect to the following elements: Whether members of special forces of the Army at entry to the qualification course have higher levels of testosterone than the average male civilian for that age group. The effects of special forces training and deployments on levels of testosterone of such members. The quality of testing for decreased testosterone levels among such members, and whether testing should be conducted at later times of the day to more accurately reflect testosterone levels.
Assistance offered to prevent and treat decreasing testosterone levels among such members. The impacts of decreased testosterone levels on readiness of such members. The impacts of decreased testosterone levels on the long-term health of such members. Anything the Under Secretary determines appropriate. Not later than one year after the date of the enactment of this Act, the Under Secretary shall submit to the congressional defense committees an interim report on the study under subsection (a), including recommendations of the Under Secretary regarding— the appropriateness of conducting a pilot program to provide testosterone replacement therapy to such members; and providing natural remedies to such members to prevent testosterone loss, including personalized meal plans, exercise plans, sleep recommendations, and actions to improve bone density and red blood count.
Not later than one year after completing the study under subsection (a), the Under Secretary shall submit to the congressional defense committees a final report regarding such study. A report under this subsection shall be submitted in an unclassified form, but may include a classified annex.